These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16413661)

  • 1. Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters.
    Lekka E; Lee LK
    Eur Urol; 2006 Oct; 50(4):806-9; discussion 809-10. PubMed ID: 16413661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
    Kuo HC
    Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
    Jeffery S; Fynes M; Lee F; Wang K; Williams L; Morley R
    BJU Int; 2007 Dec; 100(6):1302-6. PubMed ID: 17979928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.
    Schulte-Baukloh H; Schobert J; Stolze T; Stürzebecher B; Weiss C; Knispel HH
    Neurourol Urodyn; 2006; 25(2):110-5. PubMed ID: 16470519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion.
    Kuo HC
    Neurourol Urodyn; 2008; 27(8):793-6. PubMed ID: 18508331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study.
    Mehnert U; Birzele J; Reuter K; Schurch B
    J Urol; 2010 Sep; 184(3):1011-6. PubMed ID: 20643431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
    Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
    J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results.
    Karsenty G; Baazeem A; Elzayat E; Corcos J
    Can J Urol; 2006 Apr; 13(2):3027-33. PubMed ID: 16672114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
    Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
    Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder.
    Mokhless I; Gaafar S; Fouda K; Shafik M; Assem A
    J Urol; 2006 Oct; 176(4 Pt 2):1767-70; discussion 1770. PubMed ID: 16945643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor.
    Hoebeke P; De Caestecker K; Vande Walle J; Dehoorne J; Raes A; Verleyen P; Van Laecke E
    J Urol; 2006 Jul; 176(1):328-30; discussion 330-1. PubMed ID: 16753434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study.
    Werner M; Schmid DM; Schüssler B
    Am J Obstet Gynecol; 2005 May; 192(5):1735-40. PubMed ID: 15902187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
    de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G
    Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.